Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00111241|
Recruitment Status : Completed
First Posted : May 19, 2005
Results First Posted : October 5, 2018
Last Update Posted : December 14, 2018
|Condition or disease||Intervention/treatment|
|Arthralgia||Drug: aromatase inhibitors (letrozole, anastrozole)|
The mechanism of increased bone loss and fracture risk is clearly related to the depletion of estrogen production in the bone. But why there is a higher rate of reporting arthralgia, fracture and joint pain amongst women on aromatase inhibitors is not understood.
Using magnetic resonance imaging (MRI) to measure knee articular cartilage volume, we have demonstrated that post menopausal hormone therapy used for at least five years is associated with retention of articular cartilage in the knee, indicating that oestrogen may protect against the development of osteoarthritis in post menopausal women. Furthermore, we have recently observed that free testosterone is associated with loss of tibial cartilage, after taking into account age, body mass index, baseline tibial cartilage volume, tibial plateau area and total bone mineral content in healthy men. Whether an excess of testosterone to oestrogen as a consequence of aromatase inhibition has an adverse effect on articular cartilage volume warrants further investigation.
This study will include non-hysterectomised women aged 40 to 65 years who have undergone breast surgery and then commenced on aromatase inhibitors within the preceding 12 weeks. The control group (which has been fully recruited) included non-hysterectomised, healthy women aged 40 to 65 years. A MRI of the dominant knee will be used to compare changes in knee articular volume over time. A MRI will be done at baseline and again at 2 years. Changes in knee articular volume is the primary outcome. We will also use this opportunity to compare menopausal symptoms (assessed using the Menopause Quality of Life (MENQOL)questionnaire) between women treated with aromatase inhibitors and those who are not. Well-being will also be assessed using the Psychological General Well-Being index.
|Study Type :||Observational|
|Actual Enrollment :||115 participants|
|Official Title:||Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls|
|Study Start Date :||May 2005|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||December 2011|
- Drug: aromatase inhibitors (letrozole, anastrozole)
Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior studyOther Name: no other names
- Knee Cartilage Volume [ Time Frame: Baseline, two years ]change in medial and lateral articular tibial cartilage volume over two years
- Knee Subchondral Bone Expansion [ Time Frame: Baseline, Two years ]change in subchondral bone expansion area over two years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00111241
|Women's Health Research Program, Monash University, The Alfred Hospital|
|Melbourne, Victoria, Australia, 3004|
|Principal Investigator:||Susan Davis, MBBS PhD||Director Women's Health Program|